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In this manuscript we describe how the Spanish HPP-16 consortium has developed a
B/D platform with five programs focused on selected medical areas: cancer, obesity,
cardiovascular, infectious and rheumatic diseases. Each of these areas has a clinical leader
associated to a proteomic investigator with the responsibility to get a comprehensive
understanding of the proteins encoded by Chromosome 16 genes. We show how the
Proteomic strategy has enabled great advances in the area of rheumatic diseases, particularly
in osteoarthritis, with studies performed on joint cells, tissues and fluids.
This article is part of a Special Issue entitled: HUPO 2014.
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Since its foundation, the Spanish Human Proteome Project con-
sortium (SpHPP) is structured on two platforms on the basis of
ProteoRed-ISCIII network (Fig. 1). This consortium is integrated in
the global initiative Human Proteome Project [1], which aims to
develop an entire map of the proteins encoded following a gene-
centric strategy (C-HPP) [2] in order to make progress in the
understanding ofhumanbiology inhealth anddisease (B/D-HPP).
The SpHPP project was conceived on a multi-centric config-
uration, assuming the standards and integration procedures
already available in ProteoRed-ISCIII (http://www.proteored.
org), which are encompassed with the HUPO initiatives. Within
this consortium, the Spanish C-HPP platform aims to identify
and characterize previously known and unknown proteins
of Chromosome 16, whereas the B/D-HPP platform aims the
cooperation of basic researchers with clinical groups belonging
to networks of the Spanish Institute of Health (ISCIII): CIBERs
(Networks of Biomedical Research Centers) and RETICS (The-
matic Networks of Cooperative Health Research). This will
facilitate not only the comprehensive study of the products of
the 836 protein-coding genes in Chromosome 16 in diverse
sample types (cells, tissues or biofluids), but also their possible
role in disease pathogenesis, as well as their putative useful-
ness for the development of diagnosis, prognosis and treatment
strategies.2. Chromosome 16 and disease
Alterations in Chromosome 16, which comprises near 900
proteins, have been linked to several different disorders such, et al, The Spanish bi
2015), http://dx.doi.org/1as obesity, autism, neurodegenerative diseases, cancer, thal-
assemia or spondyloarthropaties. Genetics Home Reference
(http://ghr.nlm.nih.gov) lists 58 conditions that are related to
genes on Chromosome 16. These conditions include not only
common hemoglobinopathies such as alpha-thalassemia, but
also different types of cancers, inflammatory bowel diseases
such as Crohn and a number ofmetabolism-related syndromes.
A comprehensive proteomic analysis of Chr. 16 proteins will be
highly valuable for a better understanding of these pathologies.3. The Spanish biology/disease platform
With the aim of coordinating all those efforts related with
biology and disease driven projects within the HPP in Spain, the
SpHPP consortiumhas developed a BDplatformwith amanager
and five programs focused in selected medical areas, based on
those genes located in the Chromosome 16 (Fig. 2): cancer,
obesity, cardiovascular, infectious and rheumatic diseases.
Each of these areas has a clinical leader (oncologist, endocri-
nologist, cardiologist, internal medical specialist and rheuma-
tologist), and are co-chaired by a ProteoRed-ISCIII member.
Clinicians are associated to proteomic investigators with
the responsibility to get a comprehensive understanding of
the proteins encoded by the genes and their relationship
with disease. Based on the genes located in the Chromosome
16, ten diseases (colon cancer, brain cancer, breast cancer,
obesity, atherosclerosis, candidiasis, rheumatoid arthritis and
osteoarthritis) have been selected to acquire significantmedical
benefits, including improved capabilities for early detection and
diagnosis, therapeutic development and monitoring and per-
sonalized healthcare programs.ology/disease initiative within the human proteome project:
0.1016/j.jprot.2015.01.023
Fig. 1 – The SHPP-16 consortium. The C-HPP is structured on the basis of ProteoRed network, and its main objective is the
identification and proteomic characterization of previously known and unknown proteins encoded on Chromosome 16. The
B/D-HPP platform aims the cooperation of ProteoRed researchers with clinical groups belonging to networks of the Spanish
Institute of Health (ISCIII): CIBER and RETICS. This will facilitate not only the comprehensive study of proteins encoded on the
Chromosome 16 in diverse sample types (cells, tissues or biofluids), but also their possible role in disease pathogenesis, or
their putative usefulness for the development of diagnosis, prognosis and treatment strategies.
3J O U R N A L O F P R O T E O M I C S X X ( 2 0 1 5 ) X X X – X X XThe Clinical Research that is essential to validate the
proposed biomarkers on each medical area will be carried out
using the national clinical networks of the Spanish Health
Administration (National Institute of Health, ISCIII) such as the
CIBER on obesity (CIBEROBN) and different RETICS: Cardiovas-
cular Network (RIC), Cancer National Network (RTICC), Infec-
tious Pathologies Network (REIPI) and National Network of
Inflammation and Rheumatic Diseases (RIER).
Each medical area will focus on one to three specific
diseases (Fig. 2). As the quality of biological samples is a critical
point to obtain high confidence results in the HPP project,
the Spanish National Biobank Network (also belonging to
the Carlos III National Health Institute) has been involved
in the collection and storage of all selected biological fluids
and tissues that are needed to carry out clinical research in the
B/D-HPP platform, and will be the provider of clinical samples
to the project.4. Sphpp B/D initiative on rheumatic diseases
Among the five medical areas of the Spanish B/D initiative, this
article will then focus on describing the work performed in the
area of rheumatic diseases. Rheumatism is a non-specific term
used to describe any painful disorder affecting the loco-motor
system including joints, muscles, connective tissues and soft
tissues around the joints and bones. Rheumatologic disorders
include highly prevalent pathologies such as osteoarthritis,
inflammatory diseases such as rheumatoid arthritis, psoriatic
arthritis or spondyloarthropaties, and autoimmune diseasesPlease cite this article as: Ruiz-Romero C, et al, The Spanish bi
Application to rheumatic diseases, J Prot (2015), http://dx.doi.org/1such as systemic lupus erythematosus (SLE), Behçet 's syn-
drome or sarcoidosis.
There are several genes encoded in Chromosome 16 with
a possible reported role in the pathogenesis of a number of
rheumatologic disorders, which can be classified into three
groups of diseases (Table 1): A, age-related rheumatic patholo-
gies; B, inflammatory arthritis; and C, autoimmune disorders.
Osteoarthritis (OA, Group A), is the most frequent arthrop-
athy, ultimately affecting more than 10% of the population
and being the leading cause of permanent work incapacity.
It is characterized by the progressive degradation of hyaline
articular cartilage and is associated with aging [3]. Among
inflammatory arthritis (Group B), Rheumatoid arthritis (RA) is
a chronic systemic inflammatory disease of undetermined
etiology involving primarily the synovial membranes and
articular structures of multiple joints. It is associated with
progressive and severe disability and early death,mainly due to
not only increased cardiovascular disease but also to many
other comorbidities. A number of proteomic studies have been
performed to elucidate the pathogenic mechanisms of this
disease, and also to search for novel biomarkers useful for
therapymonitoring [4,5]. Apart fromRA, other relevant arthritis
such as psoriasic arthritis (PA) or spondyloarthropaties (SpAs)
should be taken into account. In this sense, a direct link
between mutations in the NOD2 gene (located on chr. 16) and
Crohn's disease has been recently found [6]. Interestingly, this
disease has a probable autoimmune origin and is associated
with the development of SpAs. Finally, other characteristic
autoimmune disorders will be the subject of our studies (Group
C, Table 1). Among these, SLE is an autoimmune connectiveology/disease initiative within the human proteome project:
0.1016/j.jprot.2015.01.023
Fig. 2 – The Spanish B/D-HPP platform. Five medical areas have been selected, based on the genes located in the Chromosome
16. These are led by a clinician and co-chaired by a ProteoRed member. Each medical area will focus on one to three specific
diseases (NAFLD: non-alcoholic fatty liver disease; SLE: systemic lupus erythematosus). Clinical samples needed to perform the
experiments will be stored and provided by the Spanish National Biobank Network. Clinical research to validate the proposed
disease biomarkers in each medical area will be carried out using the national clinical networks of the Spanish Health
Administration (Carlos III National Institute of Health, ISCIII): CIBER (CiberOBN) and RETICS (RIC, RTICC, REIPI and RIER).
4 J O U R N A L O F P R O T E O M I C S X X ( 2 0 1 5 ) X X X – X X Xtissue disease of unknown origin affecting virtually all organ
systems, with no specific cause but a number of environmental
triggers and a number of genetic susceptibilities. TheTable 1 – Genes encoded on Chromosome 16 that are
related with rheumatic diseases.
Disease Genes in Chromosome 16
A. Aging
Osteoarthritis (OA) Heparan sulfate synthases
(HS3ST2, 4 and 6)
Chondroitinsulfatase (GALNS)
MMPs (MMP2, 15 and 25)
CLUAP1
Proteins related with the
mitochondrial
function
B. Arthritis
Rheumatoid arthritis (RA)
Psoriatic arthritis
Spondyloarthropaties
ILs (IL-17, 27, 32 and 34)
ILRs (IL4R and 21R)
TNFRs (TNFRSF12A and 17)
NOD2
C. Autoimmune disorders
Systemic lupus erythematosus (SLE)
Beçet's disease
Sarcoidosis
CIITA
Integrin precursors
(ITGA-D, L, M and X)
Complement components
(C1QTNF8)
Please cite this article as: Ruiz-Romero C, et al, The Spanish bi
Application to rheumatic diseases, J Prot (2015), http://dx.doi.org/1understanding of the genetic basis of SLE has been rapidly
advanced using large-scale, case-control, candidate gene stud-
ies as well as genome-wide association studies during the last
years [7]. One of the best known associations was found
between SLE susceptibility and ITGAM or ITGAM–ITGAX region
[8], which encodes integrin alpha-M (also known as CD11b or
complement receptor 3), the α-chain of the aMβ2 integrin. Both
ITGAM and ITGAX are localized in Chromosome 16.5. Proteomic screening of the osteoarthritic joint
As a starting point for the study of rheumatic diseases from
the perspective of the HPP project, our group has performed in
the recent years several proteomic analyses on cells, tissues
and biofluids from the osteoarthritic joint, in order to increase
the knowledge about the pathogenesis of this disease [9], and
also to discover novel OA biomarker candidates [10] (Fig. 3).
The first studies were carried out on human articular
chondrocytes (which are the only cell type resident in mature
cartilage) in primary culture. These works led to the definition
of a panel of chondrocyte intracellular proteins that are
quantitatively altered in osteoarthritic cells compared to
healthy controls [11] (including chaperones and glycolytic
proteins), and also to the characterization of the chondrocyte'sology/disease initiative within the human proteome project:
0.1016/j.jprot.2015.01.023
Fig. 3 –Workflow of the Spanish B/D-HPP initiative on rheumatic diseases. Proteomic screening on disease-specific cells, tissues
andbiofluidshas led to the definition of a series of candidates relatedwithdifferent biological pathways (an example of ten of these
candidates is shown in Table 2). The development of the three HPP pillars is currently being performed: MS, through the design of
targeted MRMmethods and its application on clinical cohorts; AB, through the fabrication of antigen and antibody arrays and its
application on clinical cohorts; and KB, through the creation of business intelligence (BI) systems for knowledge management.
5J O U R N A L O F P R O T E O M I C S X X ( 2 0 1 5 ) X X X – X X Xresponse against hypoxic conditions [12], proinflammatory
mediators such as IL-1β or TNF-α [13], or drugs intended for
the treatment of osteoarthritis [14]. Apart from these studies
on whole chondrocytic proteins, proteomic profiling of chon-
drocyte mitochondria was also carried out [15,16]. These
latter works unraveled the mitochondrial dysregulation that
occurs in osteoarthritis, which has been previously reported
and was further explored in other studies [17,18]. Finally,
additional assayswere performedusing the SILAC approach to
investigate the protein profiles of the subset of chondrocyte
secreted proteins (secretome) in response to IL-1β [19] or
anti-OA drugs [20,21], considering the essential role of this
cell in synthesizing the cartilage extracellular matrix andPlease cite this article as: Ruiz-Romero C, et al, The Spanish bi
Application to rheumatic diseases, J Prot (2015), http://dx.doi.org/1maintaining its proper turnover. All these studies provide key
information about the mechanisms participating in osteoar-
thritis pathogenesis, and also those driven in cartilage cells by
either proinflammatory or therapeutic agents.
Furthermore, proteomic analyses on human articular
cartilage have also been performed. This highly specialized
tissue has an organized architecture and is composed mainly
(95–98%) of a dense extracellular matrix (ECM) including
collagens and proteoglycans that make the protein extraction
very difficult. In spite of this, some studies have compared the
protein profiles of healthy and osteoarthritic tissue [22,23].
Furthermore, other reports have focused on the peptides or
proteins released to the culturemedium fromcartilage explants.ology/disease initiative within the human proteome project:
0.1016/j.jprot.2015.01.023
6 J O U R N A L O F P R O T E O M I C S X X ( 2 0 1 5 ) X X X – X X XMost of these works showed the effect on human tissue of
metalloproteases [24] or cytokines [25] as in vitro models of
disease. Very recently, our group has conducted an analogous
study, but comparing the protein profiles released from
cartilages of healthy donors, macroscopically intact tissue of
OApatients, anddamaged tissue from the same individuals [26].
The proteins depicted in the above-mentioned works may
also have biomarker utility, as they are altered in chondrocytes
or cartilage as a consequence of the disease or the cellular
response to an outer stimulus. In this sense, great efforts are
being made in the recent years for the search of novel
biomarkers useful for diagnosis, prognosis andmonitorization
of therapeutic responses in osteoarthritis [27]. Ideally, bio-
chemicalmarkers are derived from body fluids where they can
easily be measured and monitored, such as serum, plasma or
urine, and also from joint-specific samples such as synovial
fluid. Using serum cohorts from OA patients and controls,
some studies have identified differential proteins with puta-
tive biomarker value by SELDI-TOF [28,29] and also following
an iTRAQ-based approach [30]. Alternatively, synovial fluid
provides the advantage of being located where the disease
occurs, thus containing higher concentrations of cartilage
degradation products compared to other body fluids, but
have the drawback of beingmore difficult to obtain (especially
from healthy donors or at early disease stages). Therefore,
some proteomic studies have analyzed OA synovial fluid using
samples from rheumatoid arthritis patients as comparator
group [31,32] and only two works have addressed differences
between OA and healthy controls by shotgun proteomics
[33,34], both using a small amount of samples for the analysis.6. Development of the Hpp pillars in
osteoarthritis research
All those shotgun studies reported above have led to the
definition of a series of proteins related with the pathogenesisTable 2 – Top 10 proteins detected as altered in the proteo
osteoarthritis biomarkers.
Acc. no. Protein name Chondrocy
GO:0001501 Skeletal system development
P16112 Aggrecan core protein Down
P49747 Cartilage oligomeric matrix protein ND
P05452 Tetranectin Down
GO:0051216 Cartilage development
P51884 Lumican Up
P36222 Chitinase-3-like protein 1 (YKL-40) Up
GO:0007155 Cell adhesion
P07996 Thrombospondin-1 Up
P02751 Fibronectin Up
GO:0006955 Immune response
Q92954 Proteoglycan 4 Up
P00746 Complement factor D ND
GO:0050728 Inflammatory response
P36955 Pigment epithelium-derived factor ND
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Application to rheumatic diseases, J Prot (2015), http://dx.doi.org/1of osteoarthritis, or putative biomarker candidates for early
diagnosis, prognosis and development of drugs for OA
treatment. As an example of this, Table 2 shows the top 10
proteins most commonly identified in our shotgun studies as
altered in osteoarthritis disease, either in human articular
chondrocytes [19], articular cartilage [26], synovial fluid [4] or
serum [30]. Interestingly, while some of these proteins have
been already proposed as OA biomarkers and are currently
undergoing qualification studies (such as COMP [35] or YKL-40
[36]); most of them are novel biomarker candidates for
OA. Multiplexed evaluations of these panels of proteins are
needed to advance further in the OA biomarker pipeline [10].
For this task, targeted proteomics technologies are highly
valuable, not only because of their capacity for simultaneous-
ly analyzing multiple analytes, but also because of their
potential applicability in high-throughput studies such as
clinical trials [37]. Active research will be the key for
facilitating the categorization of OA biomarkers using the
BIPEDS classification scheme that has been developed as
framework for communication in the field [38,39]: burden
of disease, investigative, prognostic, efficacy of intervention,
diagnostic or safety markers. Therefore, attention should now
be focused on the implementation of the three pillars of HPP [1]
(mass spectrometry, affinity proteomics and knowledgebase) in
order to develop improved methods and technologies that
facilitate the analysis of these candidates. This will be essential
to advance further in the understanding of the mechanisms
involved in disease, and also to qualify the biomarker utility of
the target proteins [40].
Regarding the MS pillar, the development of selected/
multiple reaction monitoring (SRM/MRM) in the context of the
HPP [41], and its increasingly frequent application in clinical
studies [42] is a highly valuable tool for alleviating the existing
bottleneck in moving markers from discovery phases to the
clinical arena. In fact, targeted analyses basedon this promising
technology have recently begun to be conducted for assessing
the levels of specific proteins in observational OA cohorts [43].mic analyses performed by our group for the search of
tes [19] Cartilage [26] Synovial
fluid [31]
Serum [30]
Down ND Up
Up Up Up
Up Up Up
Up ND Up
Up ND Up
ND ND Up
Up ND Up
Up ND Down
ND Up Up
Up ND Up
ology/disease initiative within the human proteome project:
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high-throughput technologies that can bridge the gap be-
tween basic research and in vitro diagnostic methods have
also been made in the area of affinity proteomics (AB pillar),
especially with the development of protein arrays and other
antibody-based profiling studies [44]. Different screening
strategies using protein arrays have been already applied
for profiling autoantibodies, cytokines, and bone-turnover
products in rheumatoid arthritis [45]. In osteoarthritis, we
have carried out a very recent study employing antigen
microarrays and NAPPA (nucleic acid programmable protein
arrays) to characterize the differential autoantibody profiles
in samples from OA, rheumatoid arthritis (RA) and healthy
controls [46]. At present, further studies are being performed
using antibody arrays for the screening of larger cohorts in
order to verify putative OA biomarker candidates (Lourido
et al., unpublished results).
Finally, the bioinformatics-driven knowledgebase (KB)
pillar of HPP draws upon resources that already exist such
as SwissProt/Uniprot, PRIDE, Peptide Atlas or Human Protein
Atlas databases. Although KB resources are continuously
being enhanced, there is still much room for improvement
in the area of rheumatic diseases. As an example of this, the
three tissues that aremost affected in this kind of pathologies:
cartilage, synoviumand bone, have not yet been explored in the
Human Protein Atlas initiative [47]. Therefore, our research
group is developing an initiative within our hospital (DIPROA
project) in order to join the proteomics data that have been
acquired after more than ten years of investigation on joint
tissues together with all the clinical data from the patients.
All this information is being employed to build a business
intelligence (BI) system combining data warehousing, online
analytical processing (OLAP) and knowledge discovery by data
mining (DM). This will be a highly valuable tool for knowledge
management, allowing innovation in the health care practice
that is currently being carried out in theRheumatology Services.7. Conclusions
The B/D platform of the Spanish HPP consortium is the core
for the development of proteomic studies on cancer, obesity,
cardiovascular, infectious and rheumatic diseases. The initia-
tive on rheumatic diseases will apply its experience in the
study of joint cells, tissues and body fluids for improving
osteoarthritis research on the three pillars of the HPP project,
which will be undoubtedly useful for addressing the impor-
tant unmet clinical needs of this disease and other rheumatic
pathologies.Transparency Document
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